SBR759

SBR759 is an oral, non-calcium, non-aluminum iron(III)-based phosphate binder developed for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD), particularly those receiving maintenance renal replacement therapy. The drug acts by binding dietary phosphate in the gastrointestinal tract to reduce serum phosphate levels. It is a complex formed from iron(III) chloride combined with potato starch, sucrose, and sodium carbonate. SBR759 demonstrated significant dose-dependent reductions in serum phosphate levels compared to placebo in clinical trials but was discontinued after phase II development for hyperphosphatemia. The drug was originally developed by SeBo GmbH and later by Novartis[1][2][3][6][8].

Brand names

SeborenLenziaren

Other names

iron(III)-based oral phosphate bindernon-calcium iron-based phosphate adsorbent